E
Bellerophon Therapeutics, Inc.
BLPH
OTC PK
E
Sell
8/1/2024Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/1/2024 due to a decline in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/1/2024 due to a decline in the volatility index.
D
Sell
3/7/2024Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 3/7/2024 due to a substantial increase in the growth index, volatility index and solvency index. The quick ratio increased from 1.88 to 3.49, earnings per share increased from -$0.4201 to -$0.16, and EBIT increased 58.74% from -$5.26M to -$2.17M.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 3/7/2024 due to a substantial increase in the growth index, volatility index and solvency index. The quick ratio increased from 1.88 to 3.49, earnings per share increased from -$0.4201 to -$0.16, and EBIT increased 58.74% from -$5.26M to -$2.17M.
E
Sell
8/30/2023Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/30/2023 due to a decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/30/2023 due to a decline in the total return index and volatility index.
D
Sell
8/15/2023Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index.
E
Sell
8/10/2023Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/10/2023 due to a large decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 8/10/2023 due to a large decline in the total return index and volatility index.
D
Sell
6/8/2023Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 6/8/2023 due to a substantial increase in the total return index, growth index and solvency index. Operating cash flow increased 175.05% from -$4.35M to $3.27M, earnings per share increased from -$0.53 to $0.27, and EBIT increased 129.09% from -$5.09M to $1.48M.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 6/8/2023 due to a substantial increase in the total return index, growth index and solvency index. Operating cash flow increased 175.05% from -$4.35M to $3.27M, earnings per share increased from -$0.53 to $0.27, and EBIT increased 129.09% from -$5.09M to $1.48M.
E
Sell
3/14/2023Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/23/2023Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
1/20/2023Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 1/20/2023 due to an increase in the volatility index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 1/20/2023 due to an increase in the volatility index and total return index.
D
Sell
11/22/2022Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/22/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 36.44% from -$3.67M to -$5.01M, the quick ratio declined from 3 to 2.19, and earnings per share declined from -$0.43 to -$0.531.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/22/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 36.44% from -$3.67M to -$5.01M, the quick ratio declined from 3 to 2.19, and earnings per share declined from -$0.43 to -$0.531.
D
Sell
8/18/2022Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 8/18/2022 due to an increase in the growth index. Earnings per share increased from -$0.591 to -$0.43, and operating cash flow increased 22.47% from -$4.74M to -$3.67M.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 8/18/2022 due to an increase in the growth index. Earnings per share increased from -$0.591 to -$0.43, and operating cash flow increased 22.47% from -$4.74M to -$3.67M.
D
Sell
5/23/2022Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 5/23/2022 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.05, EBIT declined 32.04% from -$4.27M to -$5.64M, and earnings per share declined from -$0.45 to -$0.591.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 5/23/2022 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.05, EBIT declined 32.04% from -$4.27M to -$5.64M, and earnings per share declined from -$0.45 to -$0.591.
D
Sell
5/16/2022Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell
5/4/2022Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 04/21/2022.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 04/20/2022.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/18/2022Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 4/18/2022 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 28.79% from -$5.59M to -$3.98M, EBIT increased 11.16% from -$4.81M to -$4.27M, and earnings per share increased from -$0.49 to -$0.45.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 4/18/2022 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 28.79% from -$5.59M to -$3.98M, EBIT increased 11.16% from -$4.81M to -$4.27M, and earnings per share increased from -$0.49 to -$0.45.
D
Sell
11/18/2021Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/18/2021 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.36 to -$0.49, and operating cash flow declined 4% from -$5.37M to -$5.59M.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/18/2021 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.36 to -$0.49, and operating cash flow declined 4% from -$5.37M to -$5.59M.
D
Sell
11/9/2021Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 11/09/2021.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index and volatility index.
D
Sell
5/12/2021Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 5/12/2021 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.8438 to -$0.58, and the quick ratio increased from 4.56 to 4.91.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 5/12/2021 due to a noticeable increase in the growth index, volatility index and solvency index. Earnings per share increased from -$0.8438 to -$0.58, and the quick ratio increased from 4.56 to 4.91.
D
Sell
4/6/2021Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 4/6/2021 due to a decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 4/6/2021 due to a decline in the total return index and volatility index.
D
Sell
3/16/2021Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 3/16/2021 due to an increase in the volatility index and valuation index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 3/16/2021 due to an increase in the volatility index and valuation index.
D
Sell
3/1/2021Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 3/1/2021 due to a decline in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 3/1/2021 due to a decline in the volatility index.
D
Sell
1/25/2021Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 1/25/2021 due to an increase in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 1/25/2021 due to an increase in the volatility index.
D
Sell
1/7/2021Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 1/7/2021 due to a decline in the growth index and volatility index. Earnings per share declined from -$0.51 to -$0.84, EBIT declined 16.94% from -$5.21M to -$6.1M, and operating cash flow declined 16.27% from -$4.23M to -$4.92M.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 1/7/2021 due to a decline in the growth index and volatility index. Earnings per share declined from -$0.51 to -$0.84, EBIT declined 16.94% from -$5.21M to -$6.1M, and operating cash flow declined 16.27% from -$4.23M to -$4.92M.
D
Sell
4/8/2020Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 4/8/2020 due to an increase in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 4/8/2020 due to an increase in the total return index and volatility index.
D
Sell
2/24/2020Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 2/24/2020 due to an increase in the valuation index, volatility index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 2/24/2020 due to an increase in the valuation index, volatility index and total return index.
E
Sell
2/7/2020Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 2/7/2020 due to a decline in the valuation index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 2/7/2020 due to a decline in the valuation index and volatility index.
D
Sell
11/12/2019Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/12/2019 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.05 to 0.09, total capital declined 28.59% from $13.76M to $9.82M, and the quick ratio declined from 2.5 to 1.84.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/12/2019 due to a significant decline in the efficiency index, valuation index and solvency index. Debt to equity increased from 0.05 to 0.09, total capital declined 28.59% from $13.76M to $9.82M, and the quick ratio declined from 2.5 to 1.84.
D
Sell
11/5/2019Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from D+ on 11/5/2019 due to a decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from D+ on 11/5/2019 due to a decline in the total return index and volatility index.
D
Sell
8/13/2019Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D+ from D on 8/13/2019 due to a significant increase in the efficiency index, valuation index and total return index. Total capital increased 8.03% from $12.73M to $13.76M.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D+ from D on 8/13/2019 due to a significant increase in the efficiency index, valuation index and total return index. Total capital increased 8.03% from $12.73M to $13.76M.
D
Sell
3/29/2019Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 3/29/2019 due to a noticeable increase in the efficiency index, solvency index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from E+ on 3/29/2019 due to a noticeable increase in the efficiency index, solvency index and total return index.
E
Sell
11/8/2018Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 11/8/2018 due to a substantial decline in the total return index, efficiency index and valuation index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D on 11/8/2018 due to a substantial decline in the total return index, efficiency index and valuation index.
D
Sell
8/17/2018Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from D+ on 8/17/2018 due to a noticeable decline in the total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from D+ on 8/17/2018 due to a noticeable decline in the total return index and volatility index.
D
Sell
8/2/2018Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D+ from D on 8/2/2018 due to a large increase in the efficiency index, total return index and valuation index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D+ from D on 8/2/2018 due to a large increase in the efficiency index, total return index and valuation index.
D
Sell
5/22/2018Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from C- on 5/22/2018 due to a significant decline in the efficiency index, valuation index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D from C- on 5/22/2018 due to a significant decline in the efficiency index, valuation index and total return index.
C
Hold
3/16/2018Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to C- from D- on 3/16/2018 due to a significant increase in the efficiency index, total return index and volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to C- from D- on 3/16/2018 due to a significant increase in the efficiency index, total return index and volatility index.
D
Sell
11/8/2017Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/8/2017 due to a significant decline in the efficiency index, valuation index and total return index. Net income declined 93.03% from -$3.93M to -$7.59M.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to D- from D on 11/8/2017 due to a significant decline in the efficiency index, valuation index and total return index. Net income declined 93.03% from -$3.93M to -$7.59M.
D
Sell
8/8/2017Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 8/8/2017 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 79.47% from -$19.14M to -$3.93M.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D from D- on 8/8/2017 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 79.47% from -$19.14M to -$3.93M.
D
Sell
2/14/2017Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 2/14/2017 due to an increase in the volatility index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 2/14/2017 due to an increase in the volatility index.
E
Sell
1/10/2017Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 1/10/2017 due to a decline in the volatility index, solvency index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 1/10/2017 due to a decline in the volatility index, solvency index and total return index.
D
Sell
8/17/2016Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 8/17/2016 due to an increase in the volatility index, solvency index and total return index.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 8/17/2016 due to an increase in the volatility index, solvency index and total return index.
E
Sell
7/27/2016Downgrade
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 7/27/2016 due to a decline in the solvency index, volatility index and efficiency index. Total capital declined 21.22% from $30.34M to $23.9M, and the quick ratio declined from 2.98 to 2.37.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E+ from D- on 7/27/2016 due to a decline in the solvency index, volatility index and efficiency index. Total capital declined 21.22% from $30.34M to $23.9M, and the quick ratio declined from 2.98 to 2.37.
D
Sell
3/16/2016Downgrade
Bellerophon Therapeutics LLC (BLPH) was downgraded to D- from D on 3/16/2016 due to a large decline in the volatility index and total return index.
Bellerophon Therapeutics LLC (BLPH) was downgraded to D- from D on 3/16/2016 due to a large decline in the volatility index and total return index.
D
Sell
3/1/2016Upgraded
Bellerophon Therapeutics LLC (BLPH) was upgraded to D from D- on 3/1/2016 due to an increase in the efficiency index.
Bellerophon Therapeutics LLC (BLPH) was upgraded to D from D- on 3/1/2016 due to an increase in the efficiency index.
D
Sell
11/2/2015Upgraded
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 11/02/2015.
Bellerophon Therapeutics, Inc. (BLPH) was upgraded to D- from E+ on 11/02/2015.
E
Sell
8/3/2015Upgraded
Bellerophon Therapeutics LLC (BLPH) was upgraded to E+ from E on 8/3/2015 due to an increase in the valuation index.
Bellerophon Therapeutics LLC (BLPH) was upgraded to E+ from E on 8/3/2015 due to an increase in the valuation index.
E
Sell
5/15/2015None
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E from U on 05/15/2015.
Bellerophon Therapeutics, Inc. (BLPH) was downgraded to E from U on 05/15/2015.
